{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:10:24Z","timestamp":1792113024510,"version":"4.4.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["schres-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.schres.2014.03.005","type":"journal-article","created":{"date-parts":[[2014,4,4]],"date-time":"2014-04-04T00:45:48Z","timestamp":1396572348000},"page":"101-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":483,"title":["Cytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"155","author":[{"given":"Rachel","family":"Upthegrove","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Manzanares-Teson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas M.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.schres.2014.03.005_bb0005","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0165-0173(99)00046-6","article-title":"Serotonin model of schizophrenia: emerging role of glutamate mechanisms","volume":"31","author":"Aghajanian","year":"2000","journal-title":"Brain Res. Rev."},{"issue":"1","key":"10.1016\/j.schres.2014.03.005_bb0010","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0920-9964(98)00140-6","article-title":"Serum levels of soluble IL-2 receptor \u03b1, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration","volume":"37","author":"Akiyama","year":"1999","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2014.03.005_bb0020","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1192\/bjp.157.1.136","article-title":"Serum interferon in first psychotic attack","volume":"157","author":"Becker","year":"1990","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2014.03.005_bb0015","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.pnpbp.2007.06.031","article-title":"The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-\u03b3","volume":"32","author":"Bian","year":"2008","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"11","key":"10.1016\/j.schres.2014.03.005_bb0025","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.jpsychires.2012.08.016","article-title":"Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse","volume":"46","author":"Borovcanin","year":"2012","journal-title":"J. Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.schres.2014.03.005_bb0030","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.schres.2013.03.027","article-title":"Antipsychotics can modulate the cytokine profile in schizophrenia: attenuation of the type-2 inflammatory response","volume":"147","author":"Borovcanin","year":"2013","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.schres.2014.03.005_bb0035","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1037\/0033-2909.98.3.569","article-title":"Season of birth in schizophrenia. a review of evidence, methodology, and etiology","volume":"98","author":"Bradbury","year":"1985","journal-title":"Psychol. Bull."},{"issue":"2\u20133","key":"10.1016\/j.schres.2014.03.005_bb0040","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0920-9964(00)00046-3","article-title":"Cytokine profiles in drug-naive schizophrenic patients","volume":"47","author":"Cazzullo","year":"2001","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2014.03.005_bb9000","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0278-5846(01)00221-4","article-title":"Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study","volume":"26","author":"Cazzullo","year":"2002","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2014.03.005_bb0045","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1177\/0269881112444941","article-title":"Minocycline benefits negative symptoms in early schizophrenia; a randomised double-blind placebo-controlled clinical trial in patients on standard treatment","volume":"26","author":"Chaudhry","year":"2012","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2014.03.005_bb0050","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/jmg.2005.030718","article-title":"The genetics of schizophrenia and bipolar disorder: dissecting psychosis","volume":"42","author":"Craddock","year":"2005","journal-title":"J. Med. Genet."},{"issue":"2","key":"10.1016\/j.schres.2014.03.005_bb0055","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.psychres.2006.08.005","article-title":"Interleukin-12 plasma levels in drug-na\u00efve patients with a first episode of psychosis: effects of antipsychotic drugs","volume":"158","author":"Crespo-Facorro","year":"2008","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2014.03.005_bb0060","first-page":"855","article-title":"White blood cells in dementia praecox and dementia paralytica","volume":"24","author":"Dameshek","year":"1930","journal-title":"Arch. Neurol. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2014.03.005_bb0065","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.schres.2014.03.005_bb0070","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bbi.2012.06.010","article-title":"Serum and gene expression profile of cytokines in first-episode psychosis","volume":"31","author":"Di Nicola","year":"2012","journal-title":"Brain Behav. Immun."},{"issue":"6","key":"10.1016\/j.schres.2014.03.005_bb0075","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.bbi.2006.02.002","article-title":"Cytokines in schizophrenia and the effects of antipsychotic drugs","volume":"20","author":"Drzyzga","year":"2006","journal-title":"Brain Behav. Immun."},{"issue":"5","key":"10.1016\/j.schres.2014.03.005_bb0080","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1192\/bjp.bp.108.052605","article-title":"Metabolic profile of antipsychotic-naive individuals with non-affective psychosis","volume":"194","author":"Fernandez-Egea","year":"2009","journal-title":"Br. J. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2014.03.005_bb0090","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.biopsych.2013.01.001","article-title":"Inflammatory Cytokines and Neurological and Neurocognitive Alterations in the Course of Schizophrenia","volume":"73","author":"Fineberg","year":"2013","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2014.03.005_bb9005","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.psychres.2011.08.014","article-title":"Inflammatory markers in antipsychotic-na\u00efve patients with nonaffective psychosis and deficit vs. nondeficit features","volume":"198","author":"Garcia-Rizo","year":"2012","journal-title":"Psychiatry research"},{"issue":"1","key":"10.1016\/j.schres.2014.03.005_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-1781(94)90042-6","article-title":"Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness","volume":"51","author":"Ganguli","year":"1994","journal-title":"Psychiatry Res."},{"issue":"3","key":"10.1016\/j.schres.2014.03.005_bb0100","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0920-9964(92)90006-Q","article-title":"Abnormalities in serum concentrations of interleukin-2, interferon-\u03b1 and interferon-\u03b3 in schizophrenia not detected","volume":"6","author":"Gattaz","year":"1992","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2014.03.005_bb0105","series-title":"Eitiology of Schizophrenia","author":"Gilmore","year":"2006"},{"issue":"1","key":"10.1016\/j.schres.2014.03.005_bb0110","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1440-1711.2005.01305.x","article-title":"Immune dysregulation and self-reactivity in schizophrenia: do some cases of schizophrenia have an autoimmune basis?","volume":"83","author":"Jones","year":"2005","journal-title":"Immunol. Cell Biol."},{"issue":"2","key":"10.1016\/j.schres.2014.03.005_bb0115","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.schres.2011.03.019","article-title":"Aripiprazole inhibits superoxide generation from phorbol-myristate-acetate (PMA)-stimulated microglia in vitro: implication for antioxidative psychotropic actions via microglia","volume":"129","author":"Kato","year":"2011","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.schres.2014.03.005_bb0120","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0920-9964(99)00171-1","article-title":"Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics","volume":"44","author":"Kim","year":"2000","journal-title":"Schizophr. Res."},{"issue":"7","key":"10.1016\/j.schres.2014.03.005_bb0125","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.pnpbp.2004.05.047","article-title":"Th1, Th2 and Th3 cytokine alteration in schizophrenia","volume":"28","author":"Kim","year":"2004","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2014.03.005_bb0130","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000213565","article-title":"Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients","volume":"59","author":"Kim","year":"2009","journal-title":"Neuropsychobiology"},{"issue":"3","key":"10.1016\/j.schres.2014.03.005_bb0135","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0920-9964(00)00156-0","article-title":"Neuroleptics normalize increased release of interleukin-1\u03b2 and tumor necrosis factor-\u03b1 from monocytes in schizophrenia","volume":"50","author":"Kowalski","year":"2001","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.schres.2014.03.005_bb0140","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0920-9964(01)00254-7","article-title":"One year outcome in first episode psychosis: influence of DUP and other predictors","volume":"54","author":"Malla","year":"2002","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.schres.2014.03.005_bb0145","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2567.2005.02166.x","article-title":"Close encounters of the monoamine kind: immune cells betray their nervous disposition","volume":"115","author":"Meredith","year":"2005","journal-title":"Immunology"},{"issue":"7","key":"10.1016\/j.schres.2014.03.005_bb0150","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2014.03.005_bb0155","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"10.1016\/j.schres.2014.03.005_bb0160","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1440-1819.2009.01945.x","article-title":"Cytokines and schizophrenia: microglia hypothesis of schizophrenia","volume":"63","author":"Monji","year":"2009","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"4","key":"10.1016\/j.schres.2014.03.005_bb0165","first-page":"205","article-title":"Inflammation and schizophrenia: pathophysiological and therapeutic aspects","volume":"52","author":"M\u00fcller","year":"2011","journal-title":"Minerva Psichiatr."},{"issue":"3","key":"10.1016\/j.schres.2014.03.005_bb0170","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2174\/157339510791823673","article-title":"Immune system and schizophrenia","volume":"6","author":"M\u00fcller","year":"2010","journal-title":"Curr. Immunol. Rev."},{"issue":"8","key":"10.1016\/j.schres.2014.03.005_bb0175","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.biopsych.2007.09.024","article-title":"Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review","volume":"63","author":"Potvin","year":"2008","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2014.03.005_bb0180","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1001\/archpsyc.1989.01810030097017","article-title":"ELevated levels of soluble interleukin 2 receptors in schizophrenia","volume":"46","author":"Rapaport","year":"1989","journal-title":"Arch. Gen. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2014.03.005_bb9010","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1600-0447.1994.tb01599.x","article-title":"Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia","volume":"90","author":"Rapaport","year":"1994","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1016\/j.schres.2014.03.005_bb0185","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2202-12-13","article-title":"Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls","volume":"12","author":"Reale","year":"2011","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.schres.2014.03.005_bb0190","series-title":"Neuropsychiatric Disorders: An Integrative Approach","first-page":"269","article-title":"The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view","author":"Schwarz","year":"2007"},{"issue":"1\u20133","key":"10.1016\/j.schres.2014.03.005_bb0195","article-title":"Pretreatment of aripiprazole and minocycline, but not haloperidol, suppresses oligodendrocyte damage from interferon-gamma-stimulated microglia in co-culture model","volume":"151","author":"Seki","year":"2013","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2014.03.005_bb0200","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.psychres.2004.04.012","article-title":"Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients","volume":"134","author":"Sirota","year":"2005","journal-title":"Psychiatry Res."},{"issue":"2","key":"10.1016\/j.schres.2014.03.005_bb0205","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0306-9877(95)90062-4","article-title":"The macrophage-T-lymphocyte theory of schizophrenia: additional evidence","volume":"45","author":"Smith","year":"1995","journal-title":"Med. Hypotheses"},{"issue":"6","key":"10.1016\/j.schres.2014.03.005_bb0210","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.biopsych.2008.10.018","article-title":"The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia","volume":"65","author":"Song","year":"2009","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2014.03.005_bb0215","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0920-9964(00)00007-4","article-title":"Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients","volume":"47","author":"Theodoropoulou","year":"2001","journal-title":"Schizophrenia research"},{"issue":"2","key":"10.1016\/j.schres.2014.03.005_bb0225","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1192\/apt.bp.113.011452","article-title":"Immune system and schizophrenia: and update for clinicians","volume":"20","author":"Upthegrove","year":"2014","journal-title":"Adv. Psychiatr. Treat."},{"issue":"3","key":"10.1016\/j.schres.2014.03.005_bb0220","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1600-0447.2009.01506.x","article-title":"The evolution of depression and suicidality in first episode psychosis","volume":"122","author":"Upthegrove","year":"2010","journal-title":"Acta Psychiatr. Scand."},{"issue":"9690","key":"10.1016\/j.schres.2014.03.005_bb0230","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","article-title":"Schizophrenia","volume":"374","author":"van Os","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.schres.2014.03.005_bb0235","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.psychres.2010.12.017","article-title":"The role of NGF and IL-2 serum level in assisting the diagnosis in first episode schizophrenia","volume":"189","author":"Xiong","year":"2011","journal-title":"Psychiatry Res."},{"issue":"2\u20133","key":"10.1016\/j.schres.2014.03.005_bb0240","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.schres.2008.09.001","article-title":"Altered interleukin-3 serum levels in drug-na\u00efve and neuroleptic-treated schizophrenic patients","volume":"106","author":"Xiu","year":"2008","journal-title":"Schizophr. Res."},{"issue":"8","key":"10.1016\/j.schres.2014.03.005_bb0245","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jpsychires.2012.04.026","article-title":"Elevated interleukin-18 serum levels in chronic schizophrenia: association with psychopathology","volume":"46","author":"Xiu","year":"2012","journal-title":"J. Psychiatr. Res."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996414001133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996414001133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T00:54:08Z","timestamp":1538700848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996414001133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":51,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0920996414001133"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2014.03.005","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2014.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2014 Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}